Search Results for “ Pfizer” – Page 14 – media

Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.

Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.
- Source: globalenergymedia
- 543
- January 17, 2018
financing Natural products organic biomolecules Pfizer small molecule
Pfizer lines up an $830M alliance with Arvinas on protein degradation

Pfizer has signed on to fund the launch of a hunt for a slate of small molecules that can degrade proteins, a key therapeutic pathway that’s been playing a role in prostate cancer and other areas.
- Source: Endpts
- 489
- January 10, 2018
C4 Therapeutics Market Views Pfizer protein degradation
Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS

Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
- Source: Prnewswire
- 448
- January 9, 2018
ALS FTLD Market Views neurodegenerative disease
Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal

Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLC struck another lucrative deal with a major pharmaceutical company. Connecticut-based Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.
- Source: Biospace
- 526
- January 8, 2018
Genentech Pfizer pharmaceutical company PROTAC small molecule therapeutics
Pfizer, Novartis and more post price hikes

It's not just specialty drugmakers raising prices in recent days. Big Pharma has pushed through a spate of increases, and while all of them are sub-10%—the cap some companies have adopted—some of them will cost payers and consumers plenty.
- Source: fiercepharma
- 466
- January 5, 2018
drugmaker Market Views price increase
Sangamo partners with Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS
- Source: Reuters
- 502
- January 4, 2018
ALS Company Insight FDA Gene therapy Pfizer
U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration(FDA) said, adding another competitor to a growing class of treatments.
- Source: Reuters
- 685
- December 25, 2017
ertugliflozin Merk New Approvals Pfizer
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active Psoriatic Arthritis

XELJANZ/XELJANZ XR, THE FIRST ORAL JAK INHIBITOR IN THE U.S. FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS, IS NOW APPROVED FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
- Source: Pfizer
- 520
- December 21, 2017
DMARDs New Approvals rheumatoid arthritis XELJANZ
OTC Viagra– Pfizer snags nod for nonprescription sales of the little blue pill for men in the U.K.

Pfizer has won a first approval for OTC Viagra. Viagra Connect, the Pfizer OTC name for its blockbuster erectile dysfunction drug, has been approved for sale in the U.K.
- Source: Fiercepharma
- 557
- December 13, 2017
erectile dysfunction drug New Approvals OTC Viagra Pfizer
Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 644
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.